P38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α activated rheumatoid arthritis fibroblast-like synoviocytes

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 515-525

  Dulos, J ^a,b   Wijnands, F P G ^a   Van den Hurk van Alebeek, J A J ^a   Van Vugt, M J H ^a   Rullmann, J A C ^a   Schot, J J G ^a   De Groot, M W G D M ^a   Wagenaars, J L ^a   Van Ravestein van Os, R ^a   Smeets, R L ^a   Vink, P M ^a   Hofstra, C L ^a   Nelissen, R L H ^a   Van Eenennaam, H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TNO   (Netherlands)

Author keywords

Chemokines; MK2; P38; Synoviocytes; TNF

Indexed keywords

CHEMOKINE; INTERLEUKIN 8; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN C JUN; SMALL INTERFERING RNA; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FIBROBLAST; GENE; INTERLEUKIN 8 GENE; MACROPHAGE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA GENE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA GENE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; UPREGULATION;

ARTHRITIS, RHEUMATOID; CELL LINE; CHEMOKINES; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MONOCYTES; NAPHTHALENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIDINES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84883520087     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. DAVIS RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-52.
2. YOSHIZAWA T, HAMMAKER D, BOYLE DL et al.: Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J. Immunol 2009; 183: 1360-67.
3. MIHARA K, ALMANSA C, SMEETS RL et al.: A potent and selective p38 inhibitor protects against bone damage in murine collageninduced arthritis: a comparison with neutralization of mouse TNF-αlpha. Br J. Pharmacol 2008; 154: 153-64.
4. NISHIKAWA M, MYOUI A, TOMITA T, TAKAHI K, NAMPEI A, YOSHIKAWA H: Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogenactivated protein kinase inhibitor FR167653. Arthritis Rheum 2003; 48: 2670-81.
5. COHEN SB, CHENG TT, CHINDALORE V et al.: Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009; 60: 335-44.
6. DAMJANOV N, KAUFFMAN RS, SPENCERGREEN GT: Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebocontrolled clinical studies. Arthritis Rheum 2009; 60: 1232-41.
7. DOMINGUEZ C, POWERS DA, TAMAYO N: p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005; 8: 421-30.
8. GENOVESE MC, COHEN SB, WOFSY D et al.: A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogenactivated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 2011; 38: 846-54.
9. MIWATASHI S, ARIKAWA Y, KOTANI E et al.: Novel inhibitor of p38 MAP kinase as an anti-TNF-αlpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 2005; 48: 5966-79.
10. CHEUNG PC, CAMPBELL DG, NEBREDA AR, COHEN P: Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 2003; 22: 5793-05.
11. SVENSSON CI, INOUE T, HAMMAKER D et al.: Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. Arthritis Rheum 2009; 60: 3229-40.
12. HAMMAKER DR, BOYLE DL, INOUE T, FIRESTEIN GS: Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 2007; 9: R57.
13. SUNDARRAJAN M, BOYLE DL, CHABAUDRIOU M, HAMMAKER D, FIRESTEIN GS: Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 2003; 48: 2450-60.
14. INOUE T, HAMMAKER D, BOYLE DL, FIRESTEIN GS: Regulation of JNK by MKK-7 in fibroblast-like synoviocytes. Arthritis Rheum 2006; 54: 2127-35.
15. MORIGUCHI T, TOYOSHIMA F, MASUYAMA N, HANAFUSA H, GOTOH Y, NISHIDA E: A novel SAPK/JNK kinase, MKK7, stimulated by TNF-αlpha and cellular stresses. EMBO J 1997; 16: 7045-53.
16. HU JH, CHEN T, ZHUANG ZH et al.: Feedback control of MKP-1 expression by p38. Cell Signal 2007; 19: 393-00.
17. MUNIYAPPA H, DAS KC: Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism. Cell Signal 2008; 20: 675-83.
18. CHEUNG PC, CAMPBELL DG, NEBREDA AR, COHEN P: Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J 2003; 22: 5793-05.
19. HAMMAKER D, FIRESTEIN GS: "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 (Suppl. 1): i77-i82.
20. HITTI E, IAKOVLEVA T, BROOK M et al.: Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006; 26: 2399-07.
21. SUN L, STOECKLIN G, VAN WS et al.: Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem 2007; 282: 3766-77.
22. POWELL DW, RANE MJ, JOUGHIN BA et al.: Proteomic identification of 14-3-3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Mol Cell Biol 2003; 23: 5376-87.
23. PHILLIPS K, KEDERSHA N, SHEN L, BLACKSHEAR PJ, ANDERSON P: Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci USA 2004; 101: 2011-16.
24. MOUREY RJ, BURNETTE BL, BRUSTKERN SJ et al.: A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010; 333: 797-07.
25. HEGEN M, GAESTEL M, NICKERSON-NUTTER CL, LIN LL, TELLIEZ JB: MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006; 177: 1913-17.
26. KOTLYAROV A, NEININGER A, SCHUBERT C et al.: MAPKAP kinase 2 is essential for LPS-induced TNF-αlpha biosynthesis. Nat Cell Biol 1999; 1: 94-7.
27. DULOS J, van D, V, KAVELAARS A, HEIJNEN CJ, BOOTS AM: CYP7B expression and activity in fibroblast-like synoviocytes from patients with rheumatoid arthritis: regulation by proinflammatory cytokines. Arthritis Rheum 2005; 52: 770-8.
28. ZHANG M, TANG J, LI X: Interleukin-1betainduced transdifferentiation of renal proximal tubular cells is mediated by activation of JNK and p38 MAPK. Nephron Exp Nephrol 2005; 99: e68-e76.
29. MAKEEVA N, ROOMANS GM, WELSH N: Role of TAB1 in nitric oxide-induced p38 activation in insulin-producing cells. Int J Biol Sci 2007; 3: 71-6.
30. HAN Z, BOYLE DL, CHANG L et al.: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108: 73-81.
31. GUMA M, KASHIWAKURA J, CRAIN B et al.: JNK1 controls mast cell degranulation and IL-1{beta} production in inflammatory arthritis. Proc Natl Acad Sci USA 2010; 107: 22122-7.
32. GUMA M, RONACHER LM, FIRESTEIN GS, KARIN M, CORR M: JNK1 deficiency limits macrophage mediated antigen-induced arthritis. Arthritis Rheum 2011;108: 1603-12.
33. STAPLES CJ, OWENS DM, MAIER JV, CATO AC, KEYSE SM: Cross-talk between the p38alpha and JNK MAPK pathways mediated by MAP kinase phosphatase-1 determines cellular sensitivity to UV radiation. J Biol Chem 2010; 285: 25928-40.
34. SONG L, LI J, ZHANG D et al.: IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J Cell Biol 2006; 175: 607-17.
35. GUAN Z, BUCKMAN SY, PENTLAND AP, TEMPLETON DJ, MORRISON AR: Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem 1998; 273: 12901-8.
36. KOCH AE: Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005; 52: 710-21.
37. TORIKAI E, KAGEYAMA Y, SUZUKI M, ICHIKAWA T, NAGANO A: The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1088-93.
38. SZEKANECZ Z, KOCH AE: Chemokines and angiogenesis. Curr Opin Rheumatol 2001; 13: 202-8.
39. GAESTEL M: MAPKAP kinases -MKs -two's company, three's a crowd. Nat Rev Mol Cell Biol 2006; 7: 120-30.
40. ANDERSON DR, MEYERS MJ, VERNIER WF et al.: Pyrrolopyridine inhibitors of mitogenactivated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007; 50: 2647-54.
41. HENDRIKS BS, SEIDL KM, CHABOT JR: Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro. BMC Syst Biol 2010; 4: 23-40.
42. SELNESS SR, DEVRAJ RV, DEVADAS B et al. Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 2011; 21: 4066-71.